ImmunoMet Therapeutics Gets $5.0M

Houston-based ImmunoMet Therapeutics, a developer of anti-tumor and immuno-oncology therapies, said Tuesday that it has raised $5.0M in a Series B financing round. The funding came from Intervest, SL Investment, NHN Investment, plus existing investors Mirae Asset Venture Investments and GNTech. The company said the funds go towards funding Phase 1 clinical studies. ImmunoMet is led by Chairman and CEO Dr. Sung-wuk Kim.